Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | GAA | P10253 | 4/20 | 1.00 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | PARP1 | P09874 | 2/20 | 0.55 |
| ▸ | CDC25B | P30305 | 7/20 | 0.54 |
| ▸ | HPGD | P15428 | 5/20 | 0.54 |
| ▸ | SAE1 | Q9UBE0 | 3/20 | 0.54 |
| ▸ | UBA2 | Q9UBT2 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | THRB | P10828 | 3/20 | 0.54 |
| ▸ | UBE2I | P63279 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | APAF1 | O14727 | 5/20 | 0.51 |
| ▸ | CASP3 | P42574 | 4/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL824574 | 1.00 | KDM4E (1.00) | KDM4EGAALOXL2ALDH1A1PARP1 | |
| SCHEMBL16591247 | 0.79 | KDM4E (0.65) | KDM4EGAALOXL2ALDH1A1PARP1 | |
| SCHEMBL24460075 | 0.78 | KDM4E (0.64) | KDM4EGAAALDH1A1PARP1HPGD | |
| SCHEMBL824579 | 0.78 | KDM4E (0.63) | KDM4EGAAALDH1A1PARP1CDC25B | |
| SCHEMBL824649 | 0.78 | KDM4E (0.63) | KDM4EGAAALDH1A1PARP1CDC25B | |
| SCHEMBL1720643 | 0.76 | LOXL2 (0.68) | KDM4EGAALOXL2ALDH1A1PARP1 | |
| SCHEMBL150458 | 0.75 | KDM4E (0.60) | KDM4EGAALOXL2ALDH1A1PARP1 | |
| SCHEMBL6448568 | 0.75 | KDM4E (0.60) | KDM4EGAALOXL2ALDH1A1PARP1 | |
| SCHEMBL1818129 | 0.75 | KDM4E (0.60) | KDM4EGAALOXL2ALDH1A1PARP1 | |
| SCHEMBL1687342 | 0.75 | KDM4E (0.60) | KDM4EGAALOXL2ALDH1A1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12338486-B2 | Single-stranded break detection in double-stranded DNA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-06-24 | — | — | US | claimed |
| EP-3781711-B1 | SINGLE-STRANDED BREAK DETECTION IN DOUBLE-STRANDED DNA | MASSACHUSETTS INST TECHNOLOGY (US) | 2024-11-20 | — | — | EP | claimed |
| US-11505827-B2 | Systems and methods for determining genetic data | Roche Sequencing Solutions, Inc. (US) | 2022-11-22 | — | — | US | claimed |
| WO-2026106389-A1 | NMT INHIBITOR AND USE THEREOF | 주식회사 이노보테라퓨틱스 | 2026-05-21 | — | — | WO | disclosed |
| WO-2026098737-A1 | NUCLEIC ACID CONJUGATE AND PHARMACEUTICAL COMPOSITION FOR LIPID DELIVERY, AND USE THEREOF | 苏州时安生物技术有限公司 | 2026-05-15 | — | — | WO | disclosed |
| US-20260110026-A1 | METHODS FOR PROPAGATING AND MAPPING LOCATION OF NON-NATURAL BASES | ILLUMINA, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4719437-A1 | CONNECTOR MODIFIED SYNTHETIC RIG-I AGONISTS AND METHODS OF USING THE SAME | RIGImmune Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20250388955-A1 | METHYLATION DETECTION WITH A NON-NATURAL/UNNATURAL BASE | ILLUMINA INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4574993-A2 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | Sequenom, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| US-12338486-B2 | Single-stranded break detection in double-stranded DNA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250157582-A1 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | SEQUENOM, INC. | 2025-05-15 | — | — | US | disclosed |
| WO-2022194799-A1 | HETEROAROMATIC COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2022-09-22 | — | — | WO | disclosed |
| CN-114724627-A | Methods and processes for non-invasive assessment of genetic variation | 塞昆纳姆股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20220205037-A1 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID | SEQUENOM, INC. | 2022-06-30 | — | — | US | disclosed |
| US-20220154265-A1 | COMPOSITIONS, METHODS, AND KITS FOR AMPLIFYING NUCLEIC ACIDS | APPLIED BIOSYSTEMS, LLC | 2022-05-19 | — | — | US | disclosed |
| CN-114457145-A | Linkers, constructs, methods, and uses for characterizing sequencing of target polynucleotides | 成都齐碳科技有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-114404581-A | Cancer vaccine | 摩登纳特斯有限公司 | 2022-04-29 | — | — | CN | disclosed |
| US-11306354-B2 | Methods and compositions for analyzing nucleic acid | SEQUENOM, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| CN-105473741-B | Methods and processes for non-invasive assessment of genetic variation | 塞昆纳姆股份有限公司 | 2022-04-19 | — | — | CN | disclosed |
| EP-3978621-A1 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | Sequenom, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388955-A1 | METHYLATION DETECTION WITH A NON-NATURAL/UNNATURAL BASE | ALPG, MPG, OGG1 | KDM4E 146/4885GAA 1536/4885LOXL2 1641/4885 |
| US-20260110026-A1 | METHODS FOR PROPAGATING AND MAPPING LOCATION OF NON-NATURAL BASES | UNG, DNMT1, TET1 | KDM4E 156/4885GAA 1224/4885LOXL2 1207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.